학술논문
Review of a promising new agentpemetrexed disodiumBased on a Satellite Symposium held in conjunction with the First European Conference on Perspectives in Bladder Cancer, Monte Carlo, Monaco, November 1617, 2001.
Document Type
Article
Author
Source
Cancer; 15 April 2003, Vol. 97 Issue: Supplement 8 p2056-2063, 8p
Subject
Language
ISSN
0008543X; 10970142
Abstract
Pemetrexed disodium (ALIMTa, [pemetrexed], LY231514; Eli Lilly and Company; Indianapolis, IN), a novel antifolate antimetabolite with multiple enzyme targets involved in both pyrimidine and purine synthesis, has entered clinical trials due to its favorable pleclinical profile. Many studies utilizing the drug, as a single or combination agent, are currently ongoing, including Phase III trials in mesothelioma, nonsmall cell lung carcinoma (NSCLC) and pancreatic cancer. Promising feasibility and activity data have been obtained with pemetrexed in combination with platinum compounds and gemcitabine. The supplementation with daily oral folate could reduce the incidence of hematologic toxicities while preserving the antitumor activity of pemetrexed. Cancer 2003;97(8 Suppl):205663. © 2003 American Cancer Society. DOI 10.1002/cncr.11279